Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 691 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Complications Clear all
Terminated Phase 4 Interventional Results available

Opioid & Steroid Use Following Tonsillectomy in Pediatric Patients

NCT04541147
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Dexamethasone, Analgesics
Drug
Lead sponsor
Duke University
Other
Eligibility
4 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Cancer

NCT00004178
View directory record Official record
Conditions
Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00886691
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
45
States / cities
Phoenix, Arizona • Burbank, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02865850
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
54
States / cities
Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 27, 2026, 4:34 PM EDT
Active, not recruiting Phase 4 Interventional

Oral Methadone in Cardiac Surgery

NCT07221617
View directory record Official record
Conditions
Pain, Postoperative, Anesthesia, Cardiac Surgery
Interventions
Methadone, oral, Methadone, intravenously
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

NCT00857623
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
AZD2066, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Bella Vista, Arkansas • National City, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

NCT01373294
View directory record Official record
Conditions
Bladder Cancer
Interventions
Bacille Calmette-Guerrin (BCG), Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

NCT01414075
View directory record Official record
Conditions
Dialysis, Anemia
Interventions
Roxadustat, Oral Iron, IV Iron
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Northridge, California • Yuba City, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

NCT01630889
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 1Phase 2 Interventional

Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00003193
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications
Interventions
amifostine trihydrate, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 2Phase 3 Interventional

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00002533
View directory record Official record
Conditions
Head and Neck Cancer, Infection, Oral Complications
Interventions
fluconazole, radiation therapy
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 27, 2026, 4:34 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819
View directory record Official record
Conditions
Advanced Solid Tumors, HER2 Mutation
Interventions
BAY2927088
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

NCT00443872
View directory record Official record
Conditions
Parkinson's Disease
Interventions
orally disintegrating selegiline (Zelapar)
Drug
Lead sponsor
Parkinson's Disease and Movement Disorder Center of Boca Raton
Other
Eligibility
30 Years to 90 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 27, 2026, 4:34 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

NCT06397872
View directory record Official record
Conditions
Renal Impairment
Interventions
100 mg Resmetirom Tablet
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 27, 2026, 4:34 PM EDT
Withdrawn Phase 2 Interventional

ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment

NCT00005645
View directory record Official record
Conditions
Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
ILX-295501
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 27, 2026, 4:34 PM EDT
Terminated Phase 1 Interventional

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

NCT02189174
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CLR457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects

NCT02313103
View directory record Official record
Conditions
Renally Impaired Subjects
Interventions
lofexidine HCl
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Not applicable Interventional

Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease

NCT00511225
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
cholecalciferol, placebo
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 27, 2026, 4:34 PM EDT
Not yet recruiting Phase 4 Interventional

Oral Versus Intravenous Acetaminophen in Lumbar Spine Surgery

NCT07203079
View directory record Official record
Conditions
Postoperative Pain
Interventions
Acetaminophen Oral Tablet, placebo oral tablet, Acetaminophen infusion, Placebo infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 27, 2026, 4:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous Versus Cyclical OCP Use in PCOS

NCT03819140
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Yasmin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 40 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 27, 2026, 4:34 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

NCT06261840
View directory record Official record
Conditions
Trichomonas Vaginitis, Bacterial Vaginitis
Interventions
Metronidazole 500 mg, Secnidazole 2000 MG
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
4
States / cities
Birmingham, Alabama • North Miami, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 27, 2026, 4:34 PM EDT